Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease - Wikidata - awgldk - TriplyDB

Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease

Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease

http://www.wikidata.org/entity/Q33984899

about

Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic Integrated physiology and systems biology of PPARα Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD The Role of Vitamins in the Pathogenesis of Non-alcoholic Fatty Liver Disease Lipid-lowering agents in the management of nonalcoholic fatty liver disease The therapeutic role of niacin in dyslipidemia management 4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine-recommendations for facing obesity, fatty liver and fibrosis epidemics.Impairments of hepatic gluconeogenesis and ketogenesis in PPARα-deficient neonatal mice.Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review.Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism.Adipose triglyceride lipase is a major hepatic lipase that regulates triacylglycerol turnover and fatty acid signaling and partitioning A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers.Dietary blueberry and bifidobacteria attenuate nonalcoholic fatty liver disease in rats by affecting SIRT1-mediated signaling pathway.Niacin Reduces Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol.Fenofibrate administration does not affect muscle triglyceride concentration or insulin sensitivity in humans.Nicotinic Acid Accelerates HDL Cholesteryl Ester Turnover in Obese Insulin-Resistant Dogs.The Lipid-lowering Effects of R-bambuterol in Healthy Chinese Volunteers: A Randomized Phase I Clinical Study.Liver fat reduction with niacin is influenced by DGAT-2 polymorphisms in hypertriglyceridemic patients Relationship between Changes in Plasma Adiponectin Concentration and Insulin Sensitivity after Niacin Therapy.Reproducibility of glucose, fatty acid and VLDL kinetics and multi-organ insulin sensitivity in obese subjects with non-alcoholic fatty liver disease.Dietary Niacin Supplementation Suppressed Hepatic Lipid Accumulation in Rabbits.Nutritional background changes the hypolipidemic effects of fenofibrate in Nile tilapia (Oreochromis niloticus).Long-term niacin treatment induces insulin resistance and adrenergic responsiveness in adipocytes by adaptive downregulation of phosphodiesterase 3B.Gut-liver interaction in triglyceride-rich lipoprotein metabolism.Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials.Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies.Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes.Nonalcoholic fatty liver disease: current issues and novel treatment approaches.Early investigational drugs targeting PPAR-α for the treatment of metabolic disease.Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies.Molecular mechanisms of fatty liver in obesity.Niacin as antidyslipidemic drug.Pharmacotherapy for Nonalcoholic Fatty Liver Disease.Plasma Lipidome Analysis by Liquid Chromatography-High Resolution Mass Spectrometry and Ion Mobility of Hypertriglyceridemic Patients on Extended-Release Nicotinic Acid: a Pilot Study.Pleiotropic effects of niacin: Current possibilities for its clinical use.Modeling of free fatty acid dynamics: insulin and nicotinic acid resistance under acute and chronic treatments.Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics.Nutrient-sensing nuclear receptors PPARα and FXR control liver energy balance.

P2860

Q24563381-6741FB62-0A62-4783-97B1-9EFAD4AD5607 Q24564130-87086750-B144-4750-A17E-8DE4719C094B Q26751258-D1177698-3ED8-4355-90F6-A3C9B4EFE853 Q26752487-FE187E03-A054-44B7-A708-BE1559C38ABB Q26752762-2C193444-8B9D-4C51-84A7-3B761D5BBEF4 Q27024352-A39DC3FF-D08A-42A9-A34B-60D9C0B1F918 Q28304559-F08B0CE5-7C70-4149-9E85-31B0A71CD527 Q30412771-39FF0904-62EA-4177-9B04-0A2E2D5BD8E8 Q33913085-94C27421-5130-4091-963C-126560FC3FA7 Q34036950-EC2F4FFD-AF24-4F1A-90FF-22ED3BF15D0E Q34168532-45BD570F-A4B0-4409-ACF5-09072D2A0586 Q34206025-7109E9FB-9003-4EDA-A1E6-BFA29B3E60CE Q34511046-03D9A96A-432D-48A8-9330-905B19C96635 Q34531843-853133C5-5B65-4ECB-84AC-26B194C6698E Q34698101-4359C65A-7558-44AF-8166-B93BE5306228 Q34805517-E773CC70-D8AE-4EEC-97A7-E3062B9132FD Q35103583-BAE04B8D-C192-47E3-9773-0E7F74F67D6F Q35772231-ED93EB12-59BF-4D37-BE14-AA0574102CAA Q35799635-D87AEC62-E985-4737-82A5-009EDCE778D8 Q35839709-BA6EF083-D3FC-4E4B-A9D8-A790DBE5AFC6 Q36206143-F6249214-DBA2-42A5-90FE-58B805E1534B Q36916256-723B8A13-C1BC-46CF-A9FC-49A809226DB1 Q37382929-FB4DB83E-C123-48BF-B309-37E86C08EA4F Q37615168-F9883A08-91E7-44D5-8808-F499007118D9 Q37655994-CE5BFED1-F089-4A04-AA5F-BD21EBBFC31D Q37892758-DF141D50-E50B-445E-A1DD-B5D378A82D34 Q37978785-3F370181-061B-4E51-8E76-F7E9B3B96956 Q37993779-C43520A3-0D5A-47F3-8492-3E3F83A78E3E Q38039980-5EA8F8C6-3BDA-4093-A304-AE3B9F3E527D Q38074898-EC11380A-0ACD-4A44-ACC0-1A456F816852 Q38325814-81BA49D7-B0E3-4ACE-97EC-FF1F29F24F86 Q38397177-D4A85D59-C1DA-450D-BB75-178FD8B3C625 Q38569945-A167B7BB-C4EF-43FC-9714-F18117C9AB5F Q38586930-1A0063C1-4248-4D5D-829D-C7595A67F180 Q38588344-0B9C9B8C-4FD4-443A-8D9C-718A3C722B6F Q38656143-F3838CBF-D84C-4325-8DD5-8F479165649E Q38810790-FB617634-9994-42FC-B2D8-D6B9371672F8 Q38948892-15C5F785-8798-4577-B370-B245D844FDC3 Q39126658-62A7A2C0-8D52-40CD-B810-2BD465DD4853 Q39175937-65D5B545-42D3-4C52-B0D3-B1734712A2CE

P2860

Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease

http://www.wikidata.org/entity/Q33984899

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Effect of fenofibrate and niac ...... nalcoholic fatty liver disease

@ast

Effect of fenofibrate and niac ...... nalcoholic fatty liver disease

@en

type

label

Effect of fenofibrate and niac ...... nalcoholic fatty liver disease

@ast

Effect of fenofibrate and niac ...... nalcoholic fatty liver disease

@en

prefLabel

Effect of fenofibrate and niac ...... nalcoholic fatty liver disease

@ast

Effect of fenofibrate and niac ...... nalcoholic fatty liver disease

@en

P1433

Q33984899-085F2B9F-D0EC-4329-8A3D-3F26A1B17F7C

P1476

Q33984899-B1A5086F-7F60-4DCF-8A84-B0EEA238E90E

P2093

Q33984899-49415083-0444-4D9E-8E59-B70A575C0693

Q33984899-6F333506-4414-4657-9272-8D7D4EFF6BDE

Q33984899-AB5CAC8B-24AC-46C5-83F2-C58D4D6D6053

Q33984899-C6DC89CA-C5A6-43E6-A180-C900A12D684D

Q33984899-DA5B105C-F27D-403A-B9F9-6DF59849956C

Q33984899-FA1B1E42-35C5-48C2-83A9-4A3807F2570F

P2860

Q33984899-054C653D-F794-405E-B0C5-A155CD1FAC3D

Q33984899-0684D44C-14BE-488D-99DC-B18A70E99C0F

Q33984899-0B2A8DDF-7753-458F-9113-612DCE4A4EA8

Q33984899-0CD8A43A-87E1-4885-A75A-B5413D6579DF

Q33984899-1D10DF1C-9627-44CD-9D7F-788DC82A8A72

Q33984899-21841025-9DEC-4764-BCFD-D0CAE22442A9

Q33984899-23829E27-A8CE-4D37-A6B8-66384D91484A

Q33984899-4CEDDB3A-21B5-4AF8-B67E-D25535A2887D

Q33984899-5050C9D3-1CDA-4C46-9F8D-E8C90F7469F1

Q33984899-5617366A-40BC-4EE0-B6F2-81BDFB0D0AE4

P304

Q33984899-5B998E82-F46A-4833-8DDF-13A17CF5FF16

P31

Q33984899-ABB4A792-545C-44AC-A172-57C01D671F2E

P356

Q33984899-70DDFDA2-3E6D-4F4F-94B0-C10572521E58

P407

Q33984899-3DCE7617-E8E3-40BB-9323-1F39BC5C9392

P433

Q33984899-0ED90C37-67A2-49CC-9CA4-782FEF4726DA

P478

Q33984899-71E6C929-B65A-4F8C-AFF3-D8A46B0DE2C0

P50

Q33984899-6C29B39A-09EA-42CF-A6D8-E268C1842A3C

P577

Q33984899-5B4276D6-2E6E-45B0-AE03-C26369DE874C

P698

Q33984899-5B81333C-80DE-4E6D-A70C-3466C584AF2D

P921

Q33984899-11B0A3A4-4A83-4BE7-88AD-3F1935ED3745

Q33984899-553C9F10-7384-44D3-9764-172B15809FD9

Q33984899-F24059C1-5433-4D20-87BE-46C4A82FDA02

P932

Q33984899-23060A2E-A231-4C04-A4CF-8BAEF3E4F543

P356

P1433

The Journal of Clinical Endocrinology and Metabolism

P1476

Effect of fenofibrate and niac ...... nalcoholic fatty liver disease

@en

P2093

B Selma Mohammed

http://www.w3.org/2001/XMLSchema#string

Bruce W Patterson

http://www.w3.org/2001/XMLSchema#string

Elisa Fabbrini

http://www.w3.org/2001/XMLSchema#string

Jennifer McCrea

http://www.w3.org/2001/XMLSchema#string

Kevin M Korenblat

http://www.w3.org/2001/XMLSchema#string

Samuel Klein

http://www.w3.org/2001/XMLSchema#string

P2860

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

Nonalcoholic fatty liver disease: a feature of the metabolic syndrome

Mechanism of action of fibrates on lipid and lipoprotein metabolism

Nonalcoholic Fatty Liver Disease: A Feature of the Metabolic Syndrome

Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production.

The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects.

Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates

Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells.

Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults.

The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression

P304

2727-2735

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/JC.2009-2622

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

95

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-04-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20371660

http://www.w3.org/2001/XMLSchema#string

P921

P932

2902076

http://www.w3.org/2001/XMLSchema#string